Sector Expertise

Stay up to date

Sale of Bertin Pharma’s pharmaceutical and biotech service businesses to Oncodesign

Sector(s)

Healthcare

Deal type

Sell your business

Date

August 2017

Countries involved

France

Client

CNIM is a French industrial engineering contractor and equipment manufacturer that operates in the sector of Environment, Energy, Defense and High Technologies

Deal

Capitalmind advised CNIM Group on the sale of Bertin Pharma’s pharmaceutical and biotech service businesses to Oncodesign

Parties

Lead team

Michel Degryck

Managing Partner
France

Kilian de Gourcuff

Partner
France

Benjamin Pasquet

Manager
France

What we did

Capitalmind supported the CNIM Group throughout the entire sale process: preparation of marketing documentation, research and selection of strategic buyers and management of carve-out issues.

About the deal

Oncodesign, completed the acquisition of the pre-clinical and clinical study activities of Bertin Pharma.
Oncodesign was founded more than 20 years ago by Dr. Philippe Genne, and is a biopharmaceutical company that specializes in ‘precision medicine’, combining medicinal chemistry, pharmacology, regulatory bioanalysis and advanced medical imaging. Oncodesign has 215 employees and subsidiaries in Canada and the United States.

By disposing of its pharma & biotech activities, the CNIM Group intends to focus on its core business, primarily in the fields of Energy, Environment, Defence and Security. Bertin Pharma currently employs 125 people and generates a turnover of 16 million euros.

Stay up to date

This website uses cookies, including third party cookies to improve your online experience. By continuing to use our website, you consent to us using cookies and web beacons. For details on how we process your personal data and for information on how you can withdraw your consent (which you may do at any time), please see our Cookie Policy and Privacy Policy.